Artificial intelligence (AI) is rapidly transforming the landscape of therapeutic antibody discovery and engineering. As the biopharmaceutical industry continues to demand faster, more precise, and cost-effective development pipelines, AI-driven solutions have emergedRead More…

Antibody-based therapeutics have emerged as one of the most successful classes of biologics for cancer treatment. Yet, the development of these complex biomolecules remains a formidable task, requiring the integration of structuralRead More…